Protriptyline hydrochloride

Research use only, not for human use.

Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA).

Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.(In Vitro):Protriptyline hydrochloride (0-70 μM; 24 hours; PC3 cells) causes cytotoxicity in PC3 cells.(In Vivo):Protriptyline hydrochloride (10 mg/kg; i.p.; for 21 days; rat model of AD) improves spatial learning and retention memory in STZ treated rats.

Protriptyline hydrochloride (0-70 μM; 24 hours; PC3 cells) causes cytotoxicity in PC3 cells. Cell Cytotoxicity Assay Cell Line:PC3 cells Concentration:50, 60 and 70 μM Incubation Time:24 hours Result:Decreased cell viability in a concentration-dependent manner.

Protriptyline hydrochloride (10 mg/kg; i.p.; for 21 days; rat model of AD) improves spatial learning and retention memory in STZ treated rats. Animal Model:Rat model of ADDosage:10 mg/kg Administration:Intraperitoneal injection; for 21 days.Result:Reduced pTau, Aβ42 and BACE-1 levels, neurodegeneration, oxidative stress and glial activation. Improved p-ERK/ERK ratio and enhanced BDNF and CREB levels by reducing NFκB and GFAP expression.

——

Endocrinology/Hormones

5-HT Receptor

Sert (Sodium-dependent)

Neurological Disease

——

1225-55-4

299.84

C19H21N·HCl

>98% (HPLC)

Soluble in DMSO

Cl.CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12

——

(-20℃)

With Ice Pack

≥ 2 years